Friday, April 12, 2019, Anaheim, California, 12:15 PM – 1:45 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the ONS 44th Annual Congress

PART 6 — Emerging Strategies in Non-Small Cell Lung Cancer

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room:
Grand Ballroom E-K (Lobby Level)
11:45 AM – 12:15 PM
Registration and Lunch Buffet

12:15 PM – 1:45 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Kelly EH Goodwin, MSN, RN, ANP-BC
Thoracic Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Joel W Neal, MD, PhD
Assistant Professor of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford University
Stanford, California

Judy Pagtama, RN, MSN, FNP-C
Nurse Practitioner
Stanford Cancer Institute
Stanford, California

Anne S Tsao, MD
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
11:45 AM – 12:15 PM — Registration and Lunch Buffet
12:15 PM – 1:45 PM — Educational Program

Module 1: Evolving Paradigms for Patients with Non-Small Cell Lung Cancer (NSCLC) and EGFR Tumor Mutations


  • Incidence and clinical implications of EGFR tumor mutations in patients with metastatic NSCLC
  • Similarities and differences among approved first-, second- and third-generation EGFR tyrosine kinase inhibitors (TKIs)
  • Data supporting the FDA approval of osimertinib as first-line therapy for metastatic NSCLC with an EGFR tumor mutation; effect of osimertinib compared to standard treatment on response rate, progression-free survival and overall survival
  • Implications of EGFR mutation type for the use of osimertinib
  • Documented activity of osimertinib in patients with CNS metastases
  • Comparative incidence of gastrointestinal and dermatologic adverse events with osimertinib versus first-/second-generation EGFR TKIs; strategies to prevent and/or ameliorate these toxicities
  • Mechanisms of treatment resistance in patients experiencing progressive disease on first-line EGFR TKI therapy; choice of second-line treatment after disease progression on first-line osimertinib
  • Sequencing immune checkpoint inhibitors for patients with metastatic NSCLC and EGFR tumor mutations

Module 2: Emergence of Immune Checkpoint Inhibition as a Therapeutic Consideration for Patients with Locally Advanced NSCLC


  • Historical outcomes associated with standard concurrent chemoradiation therapy and consolidation chemotherapy in patients with unresectable Stage III disease
  • Biologic rationale for the evaluation of immune checkpoint inhibition for patients with Stage III disease undergoing chemoradiation therapy; preclinical work supporting the synergistic effect between chemoradiation therapy and immune checkpoint inhibitors
  • Key efficacy findings with the use of consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC; patient selection for and practical implementation of sequential durvalumab in the management of unresectable Stage III NSCLC
  • Efficacy and current role of durvalumab in prespecified subgroups (eg, histology, smoking status, PD-L1 status, disease with a targetable genomic alteration)
  • Optimal timing for the use of durvalumab consolidation; impact of underlying radiation therapy-induced toxicities (eg, pneumonitis, esophagitis) on the potential introduction of durvalumab consolidation therapy
  • Rates of Grade 3/4 adverse events, including pneumonitis and other immune-mediated toxicities, and treatment discontinuation among patients receiving consolidation durvalumab
  • Optimal monitoring of patients receiving consolidation durvalumab for the presence of immune-mediated adverse events; supportive care protocols and indications for withholding or permanently discontinuing therapy

Module 3: Existing and Emerging Immunotherapeutic Combinations for NSCLC


  • Incidence of PD-L1 positivity in metastatic nonsquamous and squamous NSCLC
  • Clinical and biologic factors affecting the selection of anti-PD-1 antibody monotherapy versus combined chemotherapy/immune checkpoint inhibition for patients with metastatic NSCLC
  • Biologic rationale for the combination of anti-PD-1/PD-L1 antibody therapy with chemotherapy in metastatic NSCLC
  • Documented efficacy results with the combination of carboplatin/pemetrexed/pembrolizumab as first-line therapy for metastatic NSCLC; incremental toxicity associated with this approach compared to anti-PD-1/PD-L1 antibody monotherapy
  • Clinical research data supporting the potential synergy between anti-PD-1/PD-L1 antibodies and anti-VEGF agents
  • Key efficacy and safety findings with atezolizumab/bevacizumab in combination with carboplatin/paclitaxel for chemotherapy-naïve metastatic nonsquamous NSCLC; clinical implications of the recent FDA approval of this combination
  • Other data sets evaluating the addition of atezolizumab to chemotherapy for metastatic nonsquamous NSCLC
  • Role of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced squamous NSCLC

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Review the recent FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Review recent FDA approvals and other therapeutic advances related to the long-term management of metastatic NSCLC with an EGFR tumor mutation, and discern how this information should be applied to current off-protocol patient care.
  • Appreciate available clinical trial data with and the current role of anti-PD-1/PD-L1 antibodies in combination with chemotherapy and/or anti-angiogenic agents as first-line therapy for patients with metastatic NSCLC.
  • Educate patients about the side effects associated with recently approved therapies for NSCLC, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with NSCLC to optimize clinical and quality-of-life outcomes.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room: 
Grand Ballroom E-K (Lobby Level)

The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).


Thank you for your interest in our CNE symposia series. At this time online preregistration is closed for PART 6 — Emerging Strategies in Non-Small Cell Lung Cancer taking place on Friday, April 12, 2019. Onsite registration will be open starting at 11:30 AM on Friday, April 12th. If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside Grand Ballroom E-K (Lobby Level) at the Anaheim Marriott (700 West Convention Way, Anaheim, CA 92802). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis prioritized for oncology nurses treating patients. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at or call (800) 233-6153.